

Amer M Zeidan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6483169/publications.pdf>

Version: 2024-02-01

134
papers

3,617
citations

159585

30
h-index

175258

52
g-index

134
all docs

134
docs citations

134
times ranked

3269
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews, 2019, 36, 70-87.	5.7	484
2	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151.	27.0	335
3	Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews, 2019, 34, 1-15.	5.7	117
4	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Advances, 2018, 2, 1765-1772.	5.2	100
5	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clinical Cancer Research, 2018, 24, 3519-3527.	7.0	80
6	Current therapy of myelodysplastic syndromes. Blood Reviews, 2013, 27, 243-259.	5.7	75
7	Epigenetic therapy combinations in acute myeloid leukemia: what are the options?. Therapeutic Advances in Hematology, 2019, 10, 204062071881669.	2.5	71
8	Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts. European Journal of Haematology, 2018, 101, 711-720.	2.2	70
9	Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances, 2020, 4, 2192-2201.	5.2	68
10	Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Reviews, 2021, 47, 100773.	5.7	63
11	Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. Journal of Clinical Oncology, 2017, 35, 3417-3424.	1.6	61
12	Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal of Haematology, 2016, 175, 829-840.	2.5	59
13	The genetic and molecular pathogenesis of myelodysplastic syndromes. European Journal of Haematology, 2018, 101, 260-271.	2.2	58
14	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology, 2020, 7, e601-e612.	4.6	56
15	Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions. Seminars in Hematology, 2015, 52, 172-183.	3.4	54
16	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia, 2020, 34, 3149-3160.	7.2	54
17	Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews, 2020, 42, 100706.	5.7	54
18	NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 106-117.	4.9	54

#	ARTICLE	IF	CITATIONS
19	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 565-565.	1.4	46
20	Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. <i>Blood</i> , 2018, 131, 818-821.	1.4	45
21	Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. <i>Cancer</i> , 2016, 122, 1209-1215.	4.1	44
22	Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. <i>Cancer</i> , 2017, 123, 1703-1713.	4.1	43
23	Transforming growth factor (TGF)- β^2 pathway as a therapeutic target in lower risk myelodysplastic syndromes. <i>Leukemia</i> , 2019, 33, 1303-1312.	7.2	43
24	A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. <i>Cancer</i> , 2017, 123, 3662-3672.	4.1	39
25	There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 351-360.	2.3	37
26	Lenalidomide performance in the real world. <i>Cancer</i> , 2013, 119, 3870-3878.	4.1	37
27	Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. <i>Cells</i> , 2020, 9, 2310.	4.1	37
28	Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 705-710.	0.4	36
29	Economic burden associated with acute myeloid leukemia treatment. <i>Expert Review of Hematology</i> , 2016, 9, 79-89.	2.2	35
30	Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 327-340.	1.4	33
31	The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. <i>Blood Reviews</i> , 2016, 30, 1-10.	5.7	32
32	<p>>Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10777-10790.	1.9	32
33	Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta-analysis. <i>Transfusion</i> , 2020, 60, 2360-2369.	1.6	32
34	Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. <i>Blood Advances</i> , 2020, 4, 1615-1623.	5.2	32
35	Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. <i>Haematologica</i> , 2020, 105, 102-111.	3.5	31
36	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. <i>Blood Advances</i> , 2020, 4, 2308-2316.	5.2	29

#	ARTICLE	IF	CITATIONS
37	Therapy-related myelodysplastic syndromes, or are they?. Blood Reviews, 2017, 31, 119-128.	5.7	28
38	Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. Cancer, 2019, 125, 4241-4251.	4.1	28
39	Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS). American Journal of Medicine, 2013, 126, e25.	1.5	26
40	Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. Blood Cancer Journal, 2018, 8, 55.	6.2	26
41	Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. Annals of Hematology, 2019, 98, 339-350.	1.8	26
42	Current state of prognostication and risk stratification in myelodysplastic syndromes. Current Opinion in Hematology, 2015, 22, 146-154.	2.5	25
43	To chelate or not to chelate in MDS: That is the question!. Blood Reviews, 2018, 32, 368-377.	5.7	25
44	Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia and Lymphoma, 2020, 61, 2180-2190.	1.3	24
45	Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review of Hematology, 2020, 13, 489-499.	2.2	24
46	Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Reviews, 2021, 45, 100709.	5.7	24
47	Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. American Journal of Hematology, 2022, 97, .	4.1	24
48	Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. American Journal of Hematology, 2015, 90, 1036-1040.	4.1	23
49	A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. British Journal of Haematology, 2017, 176, 241-247.	2.5	23
50	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. Blood Reviews, 2019, 37, 100587.	5.7	23
51	Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?. Leukemia and Lymphoma, 2019, 60, 1354-1369.	1.3	23
52	Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. Oncologist, 2015, 20, 1069-1076.	3.7	20
53	Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. Cancer, 2016, 122, 1598-1607.	4.1	19
54	Myeloid disorders after autoimmune disease. Best Practice and Research in Clinical Haematology, 2019, 32, 74-88.	1.7	19

#	ARTICLE	IF	CITATIONS
55	Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. <i>Cancer</i> , 2017, 123, 3754-3762.	4.1	18
56	Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 994-1002.	5.2	18
57	Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?. <i>Expert Review of Hematology</i> , 2015, 8, 155-158.	2.2	17
58	The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1019-1036.	2.4	17
59	The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 43, 100650.	5.7	17
60	Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. <i>World Journal of Stem Cells</i> , 2016, 8, 316.	2.8	17
61	New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. <i>Expert Review of Hematology</i> , 2016, 9, 377-388.	2.2	16
62	Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. <i>Leukemia and Lymphoma</i> , 2017, 58, 982-985.	1.3	16
63	Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. <i>Leukemia and Lymphoma</i> , 2018, 59, 2723-2726.	1.3	16
64	Evolving therapies for lower-risk myelodysplastic syndromes. <i>Annals of Hematology</i> , 2020, 99, 677-692.	1.8	16
65	Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 1039-1048.	4.1	16
66	Emerging biological therapies for the treatment of myelodysplastic syndromes. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 283-300.	2.4	15
67	The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 40, 100639.	5.7	15
68	Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. <i>Leukemia and Lymphoma</i> , 2020, 61, 1178-1187.	1.3	15
69	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	1.3	15
70	Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. <i>Journal of Blood Medicine</i> , 2014, 6, 1.	1.7	14
71	Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. <i>Expert Review of Hematology</i> , 2018, 11, 715-726.	2.2	14
72	Healthcare expenses for treatment of acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 641-650.	2.2	14

#	ARTICLE	IF	CITATIONS
73	The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. <i>Blood Reviews</i> , 2021, 48, 100806.	5.7	14
74	Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. <i>Expert Review of Hematology</i> , 2017, 10, 345-364.	2.2	12
75	Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 717-729.	2.4	12
76	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 556-560.e2.	0.4	12
77	A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia. <i>Blood Reviews</i> , 2021, 47, 100736.	5.7	11
78	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 1998-2004.	2.4	11
79	Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 117, 57-66.	4.4	10
80	Histopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, , .	2.5	10
81	Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes. <i>Transfusion</i> , 2021, 61, 2830-2836.	1.6	10
82	Getting personal with myelodysplastic syndromes: is now the right time?. <i>Expert Review of Hematology</i> , 2019, 12, 215-224.	2.2	9
83	Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. <i>Blood Advances</i> , 2021, 5, 1757-1759.	5.2	9
84	Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?. <i>Leukemia and Lymphoma</i> , 2021, 62, 1949-1957.	1.3	9
85	Management of the Older Patient with Myelodysplastic Syndrome. <i>Drugs and Aging</i> , 2021, 38, 751-767.	2.7	9
86	Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. <i>Leukemia Research</i> , 2015, 39, 586-591.	0.8	8
87	More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. <i>BMC Hematology</i> , 2018, 18, 4.	2.6	8
88	Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?. <i>Expert Review of Hematology</i> , 2020, 13, 1131-1142.	2.2	8
89	The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions. <i>Current Diabetes Reviews</i> , 2016, 12, 231-239.	1.3	8
90	Effect of Erythropoiesis-Stimulating Agent Policy Decisions on Off-Label Use in Myelodysplastic Syndromes. <i>Medicare & Medicaid Research Review</i> , 2014, 4, E1-E16.	1.3	8

#	ARTICLE	IF	CITATIONS
91	Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?. <i>Leukemia and Lymphoma</i> , 2020, 61, 2295-2312.	1.3	7
92	Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst. <i>Blood Reviews</i> , 2021, 47, 100760.	5.7	7
93	Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?. <i>Cancers</i> , 2022, 14, 2434.	3.7	7
94	Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. <i>Annals of Hematology</i> , 2018, 97, 2333-2343.	1.8	6
95	What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1169-1173.	1.8	6
96	Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?. <i>Expert Review of Hematology</i> , 2013, 6, 539-542.	2.2	5
97	Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?. <i>Leukemia and Lymphoma</i> , 2018, 59, 2015-2017.	1.3	5
98	Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101132.	1.7	5
99	Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e248-e254.	0.4	5
100	High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1195-1202.	1.3	5
101	Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. <i>Cancer Management and Research</i> , 2021, Volume 13, 645-657.	1.9	5
102	Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 421-424.e2.	0.4	5
103	Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. <i>Blood Advances</i> , 2022, 6, 376-385.	5.2	5
104	Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis. <i>Leukemia and Lymphoma</i> , 2022, 63, 1534-1543.	1.3	5
105	The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. <i>Leukemia and Lymphoma</i> , 2022, 63, 1651-1659.	1.3	5
106	Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. <i>Blood Advances</i> , 2022, 6, 3339-3342.	5.2	5
107	Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D. <i>Journal of Oncology Practice</i> , 2015, 11, e190-e198.	2.5	4
108	Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1030-1032.	1.3	4

#	ARTICLE	IF	CITATIONS
109	Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 4686-4690.	5.2	4
110	Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. <i>Annals of Hematology</i> , 2022, 101, 1145-1147.	1.8	4
111	Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1766-1770.	1.4	4
112	Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. <i>Leukemia</i> , 0, , .	7.2	4
113	Chronic myelomonocytic leukemia: Are we finally solving the identity crisis?. <i>Blood Reviews</i> , 2016, 30, 381-388.	5.7	3
114	Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia. <i>Leukemia Research</i> , 2020, 90, 106315.	0.8	3
115	Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. <i>Current Opinion in Hematology</i> , 2021, 28, 110-121.	2.5	3
116	Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab. <i>Blood</i> , 2019, 134, 3809-3809.	1.4	3
117	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110434.	2.5	3
118	Conviction in the face of affliction: a case series of Jehovahâ€™s Witnesses with myeloid malignancies. <i>Annals of Hematology</i> , 2018, 97, 2245-2248.	1.8	2
119	Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials. <i>Lancet Haematology</i> , the, 2020, 7, 853-856.	4.6	2
120	Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2020, 13, 447-460.	2.2	2
121	Prognostic Models in Myelodysplastic Syndromes. , 2020, , 109-127.		2
122	Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey. <i>Blood</i> , 2018, 132, 1825-1825.	1.4	2
123	Multicenter Analysis of Treatment and Outcomes for Patient with <i>TP53</i> Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival. <i>Blood</i> , 2021, 138, 797-797.	1.4	2
124	The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia. <i>Hemato</i> , 2021, 2, 748-763.	0.6	2
125	Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016. <i>Leukemia Research</i> , 2017, 53, 8-12.	0.8	1
126	Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. <i>Leukemia and Lymphoma</i> , 2019, 60, 2584-2587.	1.3	1

#	ARTICLE	IF	CITATIONS
127	Isolated trisomy 11 in patients with acute myeloid leukemia “ is the prognosis not as grim as previously thought?*. <i>Leukemia and Lymphoma</i> , 2020, 61, 2254-2257.	1.3	1
128	Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 276-285.	2.3	1
129	Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e483-e487.	0.4	1
130	Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin. <i>Blood</i> , 2019, 134, 1302-1302.	1.4	1
131	Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19057-e19057.	1.6	0
132	Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7554-7554.	1.6	0
133	Body mass index and venetoclax-hypomethylating agent induction therapy for acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19038-e19038.	1.6	0
134	Racial disparities in patients with <i>TP53</i> mutated acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19007-e19007.	1.6	0